PUBLIC INTEREST IN THE OFF-LABEL USE OF GLUCAGON-LIKE PEPTIDE 1 AGONISTS (OZEMPIC) FOR COSMETIC WEIGHT LOSS
Main Article Content
Keywords
GLP-1 agonists, Ozempic, off-label use, weight loss, public interest
Abstract
The off-label use of Glucagon-like Peptide 1 (GLP-1) agonists, such as Ozempic, for cosmetic weight loss has garnered significant public interest in recent years. This essay explores the implications of this trend on public health, ethical considerations, and regulatory frameworks. The introduction provides a background on GLP-1 agonists and their approved medical uses, while the methods section outlines the various sources consulted to gather information for this essay. The results section highlights the benefits and risks associated with off-label use of GLP-1 agonists for weight loss. The discussion section delves into the ethical considerations surrounding this practice, including potential risks and benefits, while the conclusions summarize the main points raised in the essay. Finally, the reference list provides a comprehensive list of reputable sources consulted for this essay.
References
2. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. doi:10.1038/ijo.2013.120
3. Liraglutide for Weight Loss NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK285521/. Accessed September 13, 2021.
4. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide, a glucagon-like peptide-1 agonist, in the treatment of type 2 diabetes. Expert Opin Drug Saf. 2009;8(2):129-135. doi:10.1517/14740330803469265
5. Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi: 10.1021/acs.jmedchem.5b00726
6. Tivi S. Semaglutide - the Quest for the Holy Grail of Weight Loss. Pharm J. February 2021:2021.
7. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344. doi:10.1136/bmj.d7771
8. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A Preprandial Rise in Plasma Ghrelin Levels Suggests a Role in Meal Initiation in Humans. Diabetes. 2001;50(8):1714-1719. doi:10.2337/diabetes.50..1714
9. Knudsen LB. Glucagon-Like Peptide-1 Agonists for the Treatment of Type 2 Diabetes: Differences and Similarities. Eur J Intern Med. 2014;25(5):407-414. doi:10.1016/j.ejim.2014.03.006
10. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Abdallah Marey Aboshhran
Technician Pharmacy, King Fahd General hospital Jeddah
Saeed Ali Alqahtani
Pharmacist, King Fahd General hospital Jeddah
Yasser Mesfer Alqhtani
Technician pharmacy, King Fahd General hospital Jeddah
Ahmed Saleh Alharthi
Pharmacist, King Fahd General hospital Jeddah
Abdulrahman Hussain Fawwaz Kahl
Pharmacy Technician, Irada and Mental Health Hospital in Al-Kharj
Khaled Mohsin Ismail Khormi
Pharmacy Technician, Irada and Mental Health Hospital in Al-Kharj